Evidence map›Paper›PMID 28845402›Full record

ArticleIranian journal of public health2017

Population-based Prostate Cancer Screening in Kazakhstan.

Yevgeniy Ishkinin, Alma Zhylkaidarova, Nurzhan Nurgaliyev, Elmira Auyezova, Ainash Oshibayeva, Nadezhda Gorbunova

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Prostate cancer screening-when to start and how to screen?Translational andrology and urology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yevgeniy IshkininKazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
Alma ZhylkaidarovaKazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
Nurzhan NurgaliyevKazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
Elmira AuyezovaKazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
Ainash OshibayevaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Nadezhda GorbunovaKazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
Kazakh Institute of Oncology and Radiology · KZAl-Farabi Kazakh National University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIssues of mass screening for prostate cancer rather controversial since 2013 in 11 regions of Kazakhstan introduced a population-based screening for prostate cancer, so we need to evaluate its results.

methodsIn different regions of Kazakhstan during 2013-2015, a total of 321548 prostate-specific antigens (PSA) were determined in men aged 50-66 yr, under the Prostate Health Index (PHI) and transrectal ultrasonography (TRUS) guided prostate biopsy with histological examination.

resultsPSA level up to 4 ng/ml in 310870 (96.7%) men, PSA level between 4 and 10 ng/ml in 8 624 (2.7%) men, PSA level above 10 ng/ml in 2054 (0.6%) men. PHI was identified in 5716 (1.8%) men, of which 2867 cases were with PHI ≥ 25 (35.9%). Totally, 3680 biopsies (1.1%) of the prostate were performed. As part of the screening, 2870 cases (0.88%) of benign prostatic hyperplasia and prostatic intraepithelial neoplasia were found. Of 742 cases of prostate cancer (0.23%) were revealed. The stages of prostate cancer screening were as follows: stage I in 172 men (23.2%), stage II in 444 men (59.8%), stage III in 98 men (13.2%) and stage IV in 28 (3.8%) men. The indicators of prostate cancer early diagnosis in the I-II stages were bigger in the "screening regions" than in the "traditional diagnostics" regions: RR 1.35 95% CI (1.24 - 1.46), OR 1.84 95% CI (1.58-2.15). Prostate cancer was detected at I-II stages in the "screening" regions only by screening vs traditional diagnostics, with RR 1.64 95% CI (1.56 - 1.73), OR 4.77 95% CI (3.87-5.87).

conclusionImplementation of screening can improve the diagnosis of prostate cancer in the early stages.

Indexed as

Early diagnosisPHIPopulation-based screeningProstate cancerPSA

Identifiers

PMID28845402
PMCPMC5563873
OpenAlexW2739217948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.